Evaluation of the Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops (II) in the Treatment of Dry Eye Associated with Primary Sjögren’s Syndrome

References

• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.008.
   PubMed Web of Science ®Google Scholar
• Lemp M, Foulks GN. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop. Ocul Surf. 2007;5(2):75–92. doi:10.1016/s1542-0124(12)70081-2.
   PubMed Web of Science ®Google Scholar
• Sumida T, Azuma N, Moriyama M, et al. Clinical practice guideline for Sjogren’s syndrome 2017. Mod Rheumatol. 2017;28(3):383–408. doi:10.1080/14397595.2018.1438093.
   Web of Science ®Google Scholar
• Bjordal O, Norheim KB, Rødahl E, Jonsson R, Omdal R. Primary Sjögren’s syndrome and the eye. Surv Ophthalmol. 2020;65(2):119–132. doi:10.1016/j.survophthal.2019.10.004.
   PubMed Web of Science ®Google Scholar
• Ciurtin C, Ostas A, Cojocaru VM, Walsh SB, Isenberg DA. Advances in the treatment of ocular dryness associated with Sjögren׳s syndrome. Semin Arthritis Rheum. 2015;45(3):321–327. doi:10.1016/j.semarthrit.2015.06.007.
   PubMed Web of Science ®Google Scholar
• Zhang C, Xi L, Zhao S, et al. Interleukin-1β and tumour necrosis factor-α levels in conjunctiva of diabetic patients with symptomatic moderate dry eye: case-control study. BMJ Open. 3. 2016;6(8):e010979. doi:10.1136/bmjopen-2015-010979.
   PubMed Web of Science ®Google Scholar
• Youinou P, Pers JO. Disturbance of cytokine networks in Sjögren’s syndrome. Arthritis Res Ther. 6. 2011;13(4):227. doi:10.1186/ar3348.
   PubMed Web of Science ®Google Scholar
• Zhang XB, M VJ, Qu Y, et al. Dry eye management: targeting the ocular surface microenvironment. Int J Mol Sci. 29. 2017;18(7):1398. doi:10.3390/ijms18071398.
   PubMed Web of Science ®Google Scholar
• Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321–338. doi:10.1016/j.survophthal.2009.02.002.
   PubMed Web of Science ®Google Scholar
• Wilson SE. Inflammation: a unifying theory for the origin of dry eye syndrome. Manag Care. 2003;12:14–19.
   PubMedGoogle Scholar
• Gao J, Sana R, Calder V, et al. Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin A. Invest Ophthalmol Vis Sci. 16. 2013;54(7):4717–4733. doi:10.1167/iovs.13-11681.
   PubMed Web of Science ®Google Scholar
• Tsubota K, Fujita H, Tadano K, et al. Improvement of lacrimal function by topical application of CyA in murine models of Sjögren’s syndrome. Invest Ophthalmol Vis Sci. 2001;42(1):101–110.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group. Ophthalmology. 2000;107(4):631–639. doi:10.1016/s0161-6420(99)00176-1.
   PubMed Web of Science ®Google Scholar
• Levy O, Labbé A, Borderie V, et al. Increased corneal sub-basal nerve density in patients with Sjögren syndrome treated with topical cyclosporine A. Clin Exp Ophthalmol. 2017;45(5):455–463. doi:10.1111/ceo.12898.
   PubMed Web of Science ®Google Scholar
• Chen D, Zhang S, Bian A, et al. Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: a 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study. Medicine (Baltimore). 2019;98(31):e16710. doi:10.1097/MD.0000000000016710.
   PubMed Web of Science ®Google Scholar
• Brito-Zerón P, Sisó-Almirall A, Bové A, Kostov BA, Ramos-Casals M. Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions. Expert Opin Pharmacother. 2013;14(3):279–289. doi:10.1517/14656566.2013.767333.
   PubMed Web of Science ®Google Scholar
• Cubuk MO, Ucgul AY, Ozgur A, Ozulken K, Yuksel E. Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren’s syndrome versus non-Sjogren’s syndrome. Int Ophthalmol. 2021;41(4):1479–1485. doi:10.1007/s10792-021-01708-1.
   PubMed Web of Science ®Google Scholar
• Kang MJ, Kim YH, Chou M. Evaluation of the efficacy and safety of a novel 0.05% cyclosporin a topical nanoemulsion in primary Sjögren’s syndrome dry eye. Ocul Immunol Inflammation. 2020;28(3):370–378. doi:10.1080/09273948.2019.1587470.
   PubMed Web of Science ®Google Scholar
• Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int. 2015;112(5):71–81. doi:10.3238/arztebl.2015.0071.
   PubMed Web of Science ®Google Scholar
• Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol. 2013;32(1):19–41. doi:10.3109/08830185.2012.748052.
   PubMed Web of Science ®Google Scholar
• Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2013;130(1):90–100. doi:10.1001/2Farchophthalmol.2011.364.
   Google Scholar
• Stern ME, Beuerman RW, Fox RI, et al. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol. 1998;438:643–651. doi:10.1007/978-1-4615-5359-5_91.
   PubMed Web of Science ®Google Scholar
• Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17(6):584–589. doi:10.1097/00003226-199811000-00002.
   PubMed Web of Science ®Google Scholar
• Bron A, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510. doi:10.1016/j.jtos.2017.05.011.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017;124(11S):S4–S13. doi:10.1016/j.ophtha.2017.07.010.
   PubMed Web of Science ®Google Scholar
• Periman LM, Perez VL, Saban DR, Lin MC, Neri P. The immunological basis of dry eye disease and current topical treatment options. J Ocul Pharmacol Ther. 2020;36(3):137–146. doi:10.1089/2Fjop.2019.0060.
   PubMed Web of Science ®Google Scholar
• Baudouin C. The pathology of dry eye. Surv Ophthalmol. 2001;45(Suppl 2):S211–S220. doi:10.1016/s0039-6257(00)00200-9.
   PubMed Web of Science ®Google Scholar
• Tan X, Sun S, Liu Y, et al. Analysis of Th17-associated cytokines in tears of patients with dry eye syndrome. Eye (Lond). 2014;28(5):608–613. doi:10.1038/eye.2014.38.
   PubMed Web of Science ®Google Scholar
• Vagge A, Senni C, Bernabei F, et al. Therapeutic effects of lactoferrin in ocular diseases: from dry eye disease to infections. Int J Mol Sci. 2020;21(18):6668. doi:10.3390/ijms21186668.
   PubMed Web of Science ®Google Scholar
• Danjo Y, Lee M, Horimoto K, Hamano T. Ocular surface damage and tear lactoferrin in dry eye syndrome. Acta Ophthalmol. 1994;72(4):433–437. doi:10.1111/j.1755-3768.1994.tb02791.
   PubMed Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118(11):1489–1496. doi:10.1001/archopht.118.11.1489.
   PubMedGoogle Scholar
• Ogawa Y, Shimizu E, Tsubota K. Interferons and dry eye in Sjögren’s syndrome. Int J Mol Sci. 10. 2018;19(11):3548. doi:10.3390/ijms19113548.
   PubMed Web of Science ®Google Scholar
• Moon I, Kang HG, Yeo A, et al. Comparison of ocular surface mucin expression after topical ophthalmic drug administration in dry eye-induced mouse model. J Ocul Pharmacol Ther. 2018;34(9):612–620. doi:10.1089/jop.2018.0005.
   PubMed Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120(3):330–337. doi:10.1001/archopht.120.3.330.
   PubMedGoogle Scholar
• Nichols K. The international workshop on meibomian gland dysfunction: introduction. Invest Ophthalmol Vis Sci. 2011;52(4):1917–1921. doi:10.1167/iovs.10-6997.
   PubMed Web of Science ®Google Scholar
• Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011;52(4):1938–1978. doi:10.1167/iovs.10-6997c.
   PubMed Web of Science ®Google Scholar
• Kovács B, Láng B, Takácsi-Nagy A, et al. Meibom-mirigy-diszfunkció és a száraz szem: diagnosztikai és kezelési lehetőségek [Meibomian gland dysfunction and dry eye: diagnosis and treatment]. Orv Hetil. 2021;162(2):43–51. doi:10.1556/650.2021.31958.
   PubMedGoogle Scholar
• Sullivan DA, Dana R, Sullivan R, et al. Meibomian gland dysfunction in primary and secondary Sjögren syndrome. Ophthalmic Res. 2018;59(4):193–205. doi:10.1159/000487487.
   PubMed Web of Science ®Google Scholar
• Hyon JY, Lee YJ, Yun PY. Management of ocular surface inflammation in Sjögren syndrome. Cornea. 2007;26(9 Suppl 1):S13–5. doi:10.1097/ICO.0b013e31812f6782.
   PubMed Web of Science ®Google Scholar
• Devecı H, Kobak S. The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren’s syndrome. Int Ophthalmol. 2014;34(5):1043–1048. doi:10.1007/s10792-014-9901-4.
   PubMed Web of Science ®Google Scholar
• Small DS, Acheampong A, Reis B, et al. Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther. 2002;18(5):411–418. doi:10.1089/10807680260362696.
   PubMed Web of Science ®Google Scholar
• Wan KH, Chen LJ, Young AL. Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf. 2015;13(3):213–225. doi:10.1016/j.jtos.2014.12.006.
   PubMed Web of Science ®Google Scholar
• Chen M, Gong L, Sun X, et al. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial. J Ocul Pharmacol Ther. 2010;26(4):361–366. doi:10.1089/jop.2009.0145.
   PubMed Web of Science ®Google Scholar
• Schrell C, Cursiefen C, Kruse F, Jacobi C. Topical cyclosporine A 0.05% in the treatment of keratoconjunctivitis sicca. Klin Monbl Augenheilkd. 2012;229(5):548–553. doi:10.1055/s-0031-1281862. German.
   PubMed Web of Science ®Google Scholar
• Clearkin L. Concerns over efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 8. 2017;27(6):e193. doi:10.5301/ejo.5001044.
   PubMed Web of Science ®Google Scholar
• Pérez-Rico C, Germain F, Castro-Rebollo M, Moreno-Salgueiro A, Teus MÁ. Effect of topical 0.05% cyclosporine A on corneal endothelium in patients with dry eye disease. Int J Ophthalmol. 18. 2013;6(4):471–474. doi:10.3980/j.2222-3959.2013.04.12.
   PubMed Web of Science ®Google Scholar
• Othman TM, Mousa A, Gikandi PW, AbdelMabod M, Abdelrahman AM. Efficacy and safety of using topical cyclosporine A for treatment of moderate to severe dry eye disease. Saudi J Ophthalmol. 2018;32(3):217–221. doi:10.1016/j.sjopt.2018.06.001.
   PubMed Web of Science ®Google Scholar